Google
MGX — METAGENOMI, INC. COMMON STOCK (Healthcare >> Biotechnology)
MGX FAQ
What is MGX's ROE?
METAGENOMI, INC. COMMON STOCK reports a Return on Equity (ROE) of -62.33%.
What is MGX's dividend yield?
METAGENOMI, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is MGX's Deepscope Quality Score?
Deepscope rates MGX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MGX?
Deepscope's AI Timing Score for MGX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MGX belong to?
METAGENOMI, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.28
Price
-0.05
(-3.76%)
Day Change
|
|
|---|
MGX, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.28 |
| PBV / Sector |
0.36 / 4.63
GREAT
|
| Earning Per Share | -2.20 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.27 M
GREAT
|
| Average 1W Daily Value |
0.24 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:03 |
| Symbol | MGX |
| Name | METAGENOMI, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 37.65 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 50.07 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5959 Horton Street, Emeryville, CA, United States, 94608
Phone: 510 871 4880
Website: https://metagenomi.co
Employees: 119
Sector: Healthcare >> Biotechnology
Description: Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
